Notre Dame Describes LYMErix Disease (Immunosuppression)

[Kathleen]

To: kathleen...@hhs.gov, francis...@nih.hhs.gov,
margaret...@fda.hhs.gov, dwh...@forbes.com,
ca...@drcarolgoodheart.com, lPick...@cdc.gov, Durlan...@yale.edu,
Aa...@columbia.edu, gary_w...@nymc.edu,
scientifi...@ostp.gov, pkru...@princeton.edu,
Stanle...@fiu.edu, margaret...@hhs.fds.gov,
emcsw...@niaid.nih.gov, afa...@niaid.nih.gov,
Spin...@yahoogroups.com, kshe...@calea.org, fit...@gmail.com,
patrick.f...@usdoj.gov, model...@sbcglobal.net,
jdr...@nejm.org, let...@courant.com, Jgerb...@cdc.gov,
michae...@ct.gov, con...@po.state.ct.us, executive-
edi...@nytimes.com, managin...@nytimes.com, news-
ti...@nytimes.com, biz...@nytimes.com, for...@nytimes.com,
nati...@nytimes.com, dv...@cdc.gov, brigidc...@optonline.net,
tr...@hotmail.com, illino...@aol.com, jle...@courant.com,
tinaj...@yahoo.com, jhorn...@fff.org, thomas...@usdoj.gov,
thoma...@ct.gov, kur...@washpost.com, georg...@washpost.com,
p...@allegorypress.com, commissi...@po.state.ct.us,
brans...@comcast.net, vts...@comcast.net, o...@po.state.ct.us,
freet...@charter.net, scott....@po.state.ct.us,
govern...@po.state.ct.us, attorney...@ct.gov,
randall...@usdoj.gov, Robert....@yale.edu, editor@greenwich-
post.com, harol...@yale.edu, sedm...@nswbc.org, rrmcg...@aol.com,
fr...@nytimes.com, saint....@sbcglobal.net
Cc: fra...@ucia.gov, dr-ahma...@president.ir,
eugener...@washpost.com, bmi...@newstimes.com, tr...@hotmail.com,
rast...@aol.com, billc...@gmail.com, amcg...@rms-law.com,
rjmu...@aol.com, paulcrai...@yahoo.com,
criminal...@usdoj.gov, karla.d...@usdoj.gov,
christophe...@usdoj.gov, richar...@yale.edu,
harol...@yale.edu, james.p...@yale.edu, inq...@aldf.com,
ly...@idsociety.org, meganm...@theatlantic.com

Subject: Notre Dame Describes LYMErix Disease (Immunosuppression)

Date: Sep 22, 2011 3:58 AM

ARTICLE BELOW

See more at
http://www.actionlyme.org
and
http://www.fda.gov/ohrms/dockets/ac/01/slides/3680s2.htm
and
http://projectreporter.nih.gov/project_info_description.cfm?aid=7750609&icde=0
and
http://www.actionlyme.org/101016.htm

This is the reason LYMErix
was removed from the market
under threat from the FDA.

What is prosecutable is the
lies about the outcome of LYMErix
to the FDA and the public,
http://www.actionlyme.org/DICKSON_FDA_SUBMISSION_FULL.htm
and of course, the Dearborn
Stunt:
http://www.actionlyme.org/PLUMSTUPID.htm



========================


http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077381/?tool=pubmed

Macrophages infected with Mycobacterium tuberculosis (M.tb) are known
to be refractory to IFN-γ stimulation. Previous studies have shown
that M.tb express components such as the 19-kDa lipoprotein and
peptidoglycan that can bind to macrophage receptors including the Toll-
like receptor 2 resulting in the loss in IFN-γresponsiveness. However,
it is unclear whether this effect is limited to infected macrophages.
We have previously shown that M.tb-infected macrophages release
exosomes which are 30-100 nm membrane bound vesicles of endosomal
origin that function in intercellular communication. These exosomes
contain mycobacterial components including the 19-kDa lipoprotein
[LIKE LYMERIX and SPIROCHETAL SHEDDING KNOWN AS BLEBBING-KMD] and
therefore we hypothesized that macrophages exposed to exosomes may
show limited response to IFN-γ stimulation.

KMDickson